A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension
Journal of Ocular Pharmacology and Therapeutics, Ahead of Print. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - April 10, 2024 Category: Opthalmology Authors: Avinash Mishra Mohini Agrawal Anchal Tripathi Atul Bhirud Lt Col Rajnish Kumar Brig Baranwal Vinod K Source Type: research
Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment
This study focused on using a 3D printing (3DP) method for the manufacturing of an ocular, implantable, sustained-release drug delivery system (DDS). Polycaprolactone (PCL), and PCL with 5 or 10% TML implants were manufactured using a one-step 3DP process. Their physicochemical characteristics were analysed using light microscopy, scanning electronic microscopy (SEM), differential scanning calorimetry (DSC) / thermal gravimetric analysis (TGA), and Fourier-transform infrared spectroscopy (FTIR). The in vitro drug release was evaluated by UV-spectrophotometry. Finally, the effect of the implants on cell viability in human t...
Source: Cell Research - April 5, 2024 Category: Cytology Authors: Fathima Paleel Mengqi Qin Aristides D Tagalakis Cynthia Yu-Wai-Man Dimitrios A Lamprou Source Type: research
Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment
This study focused on using a 3D printing (3DP) method for the manufacturing of an ocular, implantable, sustained-release drug delivery system (DDS). Polycaprolactone (PCL), and PCL with 5 or 10% TML implants were manufactured using a one-step 3DP process. Their physicochemical characteristics were analysed using light microscopy, scanning electronic microscopy (SEM), differential scanning calorimetry (DSC) / thermal gravimetric analysis (TGA), and Fourier-transform infrared spectroscopy (FTIR). The in vitro drug release was evaluated by UV-spectrophotometry. Finally, the effect of the implants on cell viability in human t...
Source: Cell Research - April 5, 2024 Category: Cytology Authors: Fathima Paleel Mengqi Qin Aristides D Tagalakis Cynthia Yu-Wai-Man Dimitrios A Lamprou Source Type: research
Timolol in the treatment of hard-to-heal wounds: a comprehensive review
Journal of Wound Care,Volume 33, Issue 4, Page 243-252, April 2024. (Source: Journal of Wound Care)
Source: Journal of Wound Care - April 4, 2024 Category: Nursing Authors: David Cornwell Zachary Goldstein Bopha Chrea Robert McLafferty Source Type: research
The Use of Timolol for Wound Healing—A Review
AbstractPurpose of ReviewIn recent years, drug repurposing has gained traction as a method to accelerate the availability of effective treatments. This review focuses on timolol, originally a topical non-selective β-adrenergic antagonist used for increased intraocular pressure and glaucoma, and its emerging role in the wound healing landscape—a field that has been lacking in effective treatments for decades.Recent FindingsPreclinical and clinical studies have highlighted timolol ’s promise as a therapeutic option in wound healing. Its benefits are attributed to various mechanisms including improved re-epithelial...
Source: Current Dermatology Reports - February 22, 2024 Category: Dermatology Source Type: research
Differentiating stages of functional vision loss from glaucoma using the Disc Damage Likelihood Scale and cup:disc ratio
Conclusion
This study indicates that both structural staging systems can differentiate severe/end-stage glaucoma from less severe disease, with a moderate advantage of DDLS over CDR. Clinical examination of the optic disc plays an important role in addition to functional assessment when managing severe/end-stage glaucoma. (Source: British Journal of Ophthalmology)
Source: British Journal of Ophthalmology - February 21, 2024 Category: Opthalmology Authors: Philippin, H., Matayan, E. N., Knoll, K. M., Macha, E., Mbishi, S., Makupa, A., Matsinhe, C. D., da Gama, I. V., Monjane, M. J., Ncheda, J. A., Mulobuana, F. A. F., Muna, E., Guylene, N. F., Gazzard, G., Marques, A. P., Shah, P., Macleod, D., Makupa, W., Tags: Open access Glaucoma Source Type: research
Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)
Glaucoma refers to a group of optic nerve diseases associated with progressive vision loss and is one of the leading causes of irreversible blindness worldwide.1 Elevated intraocular pressure (IOP) is a key contributing factor for the progression of open-angle glaucoma (OAG) and ocular hypertension (OHT).2 IOP reduction remains a key goal for glaucoma therapy2 and reducing elevated IOP with ocular hypotensive medication has been demonstrated to delay disease progression.3-5 (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - February 21, 2024 Category: Opthalmology Authors: Jason Bacharach, Jacob W. Brubaker, David G. Evans, Fenghe Lu, Noriko Odani-Kawabata, Takaharu Yamabe, David L. Wirta Tags: Original Articles Source Type: research
The effect of combination therapy with intravitreal bevacizumab and topical timolol –dorzolamide eye drops on diabetic macular edema: a double-blind randomized controlled trial
ConclusionOur findings support the short-term effectiveness of topical timolol –dorzolamide as adjunctive therapy to IVB injections in managing center-involving DME in terms of anatomical and visual outcomes. Trial registration: Clinicaltrials.gov NCT05083689 (October 19, 2021). (Source: International Ophthalmology)
Source: International Ophthalmology - February 20, 2024 Category: Opthalmology Source Type: research
Co-delivery of Brinzolamide and Timolol from Micelles-laden Contact Lenses: In vitro and In Vivo Evaluation
In conclusionThe manuscript delineates the development of a safe and efficacious micelle-loaded contact lens drug delivery system, which presents a novel therapeutic alternative for the management of glaucoma.Graphical Abstract (Source: Pharmaceutical Research)
Source: Pharmaceutical Research - February 16, 2024 Category: Drugs & Pharmacology Source Type: research
Timolol maleate, a β blocker eye drop, improved edema in a retinal vein occlusion model
CONCLUSIONS: These results indicate that timolol eye drops may be a potential option for RVO treatment.PMID:38222457 | PMC:PMC10784217 (Source: Molecular Vision)
Source: Molecular Vision - January 15, 2024 Category: Molecular Biology Authors: Shinichiro Fuma Yae Hidaka Anri Nishinaka Hiroto Yasuda Kota Aoshima Shinsuke Nakamura Hideaki Hara Masamitsu Shimazawa Source Type: research
Human experience and efficacy of omidenepag isopropyl (Eybelis ®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug
Curr Opin Pharmacol. 2024 Jan 1;74:102426. doi: 10.1016/j.coph.2023.102426. Online ahead of print.ABSTRACTMore than 75 million people worldwide suffer from ocular hypertension (OHT)-associated retinal and optic nerve degenerative diseases that cause visual impairment and can lead to blindness. In an effort to find novel pharmaceutical therapeutics to combat OHT with reduced side-effect potential, several emerging drug candidates have advanced to human proof-of-concept in recent years. One such compound is a nonprostaglandin (non-PG) EP2-receptor-selective agonist (omidenepag isopropyl ester). Omidenepag (OMD; free acid for...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Najam A Sharif Source Type: research
Human experience and efficacy of omidenepag isopropyl (Eybelis ®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug
Curr Opin Pharmacol. 2024 Jan 1;74:102426. doi: 10.1016/j.coph.2023.102426. Online ahead of print.ABSTRACTMore than 75 million people worldwide suffer from ocular hypertension (OHT)-associated retinal and optic nerve degenerative diseases that cause visual impairment and can lead to blindness. In an effort to find novel pharmaceutical therapeutics to combat OHT with reduced side-effect potential, several emerging drug candidates have advanced to human proof-of-concept in recent years. One such compound is a nonprostaglandin (non-PG) EP2-receptor-selective agonist (omidenepag isopropyl ester). Omidenepag (OMD; free acid for...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Najam A Sharif Source Type: research
Human experience and efficacy of omidenepag isopropyl (Eybelis ®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug
Curr Opin Pharmacol. 2024 Jan 1;74:102426. doi: 10.1016/j.coph.2023.102426. Online ahead of print.ABSTRACTMore than 75 million people worldwide suffer from ocular hypertension (OHT)-associated retinal and optic nerve degenerative diseases that cause visual impairment and can lead to blindness. In an effort to find novel pharmaceutical therapeutics to combat OHT with reduced side-effect potential, several emerging drug candidates have advanced to human proof-of-concept in recent years. One such compound is a nonprostaglandin (non-PG) EP2-receptor-selective agonist (omidenepag isopropyl ester). Omidenepag (OMD; free acid for...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Najam A Sharif Source Type: research
